On November 2, 2021 MannKind Corporation (Nasdaq:MNKD) reported that it will release its 2021 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, November 9, 2021 (Press release, Mannkind, NOV 2, 2021, View Source [SID1234594110]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven B. Binder.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company’s website at Events & Presentations View Source A replay will also be available on MannKind’s website for 14 days.

On November 2, 2021 Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported that management will participate in the following upcoming investor conferences (Press release, Scholar Rock, NOV 2, 2021, View Source [SID1234594151]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Credit Suisse 30th Annual Virtual Healthcare Conference on Tuesday, November 9th, 2021 at 8:50 a.m. ET.
Cowen 5th Annual IO Next Virtual Summit on Monday, November 15th, 2021 at 8:15 a.m. ET.
12th Annual Jefferies Global Healthcare Conference in London on Wednesday, November 17th, 2021 at 5:00 p.m. GMT (11:00 a.m. ET).
33rd Annual Piper Sandler Virtual Healthcare Conference on November 30th-December 2nd, 2021. The webcast will be available beginning at 10:00 a.m. ET on November 22.
A live webcast of presentations at the Credit Suisse, Cowen and Jefferies conferences may be accessed by visiting the Investors & Media section of the Scholar Rock website at View Source All these webcasts will be archived and available on the Company’s website for approximately 90 days following the presentation.

On November 2, 2021 Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) Biofrontera AG (ISIN: DE0006046113) has reported the closing of the successful IPO of its US subsidiary Biofrontera Inc. on Nasdaq (see also ad hoc announcement of November 2, 2021) (Press release, Biofrontera, NOV 2, 2021, View Source [SID1234594327]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The successfully completed IPO provides Biofrontera Inc. with the financial resources necessary to expand its marketing and sales activities. In addition, the listing on Nasdaq offers U.S. companies the opportunity to flexibly exploit market opportunities and respond rapidly to market risks.

Similar financing opportunities cannot be created by Biofrontera AG, which is restricted in many respects by the German capital market and corporate law regulations.

Professor Dr. Hermann Lübbert, founder and CEO of Biofrontera AG, commented: "The IPO and the associated access to one of the largest technology markets, together with the growth-oriented US corporate law, provides Biofrontera Inc. with the opportunity for further financing independently of Biofrontera AG. The high trading volumes already on the first two trading days indicate solid investor interest."

In the U.S., the current market share of Ameluz within the Photodynamic Therapy (PDT) sector is about 24%. Considering the still limited total market share of less than 2% for PDT in the treatment of actinic keratoses, our company’s declared goal is the exploitation of the growth potential through increased investments in marketing and sales. Furthermore, Biofrontera Inc. is strengthening the marketing of its second product Xepi, a topical antibiotic that is approved for the treatment of impetigo, a highly infectious bacterial skin infection, and effective even against antibiotic-resistant bacteria.

Biofrontera AG will directly benefit from the PDT sales growth of Biofrontera Inc. through a license and supply agreement. Under this agreement, Biofrontera Inc. acquires Ameluz and the PDT lamp BF-RhodoLED from Biofrontera AG. Up to annual Ameluz sales of USD 30 million, Biofrontera Inc. pays 50% of sales as a transfer price. This share decreases to 40% for sales from 30 to 50 Mio. USD and to 30% above 50 Mio. USD in sales, respectively, accounting for the associated higher sales costs.

Patents, drug approvals and all sales outside the USA, as well as future research results outside the further development of Ameluz will be exclusively owned by Biofrontera AG. Following the successful IPO of Biofrontera Inc., Biofrontera AG will be able to focus its financial resources on research and development and on marketing its products on the European and other international markets.

On November 2, 2021 Almac Sciences, a member of the Almac Group, reported that it has initiated a new flow chemistry collaboration with Irish Manufacturing Research (IMR) to design and 3D print novel flow reactors and static mixers (Press release, Almac, NOV 2, 2021, View Source [SID1234594653]). The planned project takes advantage of the design freedom of Additive Manufacturing (AM, an industrialised approach to 3D printing) to make bespoke reactors allowing previously unobtainable chemistry plausible.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Flow chemistry is gaining momentum in its application within the pharma industry by unlocking reaction chemistry not possible in traditional batch mode. At Almac, exploiting continuous flow technology aims to offer clients the best available technology to meet their demanding processing needs of today whilst securing manufacture for the future, by expediting the development of processes where the target chemistry is inherently difficult to scale due to safety concerns.

IMR is a leading manufacturing Research and Technology Organisation (RTO) with labs and industrial pilot lines in Ireland. IMR’s ambition is to accelerate the implementation of key elements of Ireland’s industrial strategy and enable Irish based manufacturers to be early adopters of new technology.

Lead collaborator at IMR, Tristan McCallum said: "I am very excited about our collaboration with Almac Sciences where, with our expertise at IMR, we can support Irish industry to design and produce AM reactors and mixers locally; using the advanced additive manufacturing capability here in Ireland."
Dr Megan Smyth, Team Leader, Custom and Flow Chemistry at Almac Sciences commented: "This collaboration enables us to move to the next step of our flow chemistry service allowing immediate access to printed reactors with unique properties. This project will ensure we continue to offer our customers best-in-class technical solutions to address the many challenges that contract chemistry brings. As an industry, we need to develop innovative manufacturing routes that opens up access to new raw material supply chains with more secure and mature options. Flow chemistry can assist with this and we are delighted to be progressing it with IMR."

Earlier this year, Almac Sciences invested over £5million to establish its R&D centre to support increased client demand for its established biocatalysis, flow chemistry and peptides solutions. "

On November 2, 2021 Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, reported the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Superstring (Press release, Shoreline Biosciences, NOV 2, 2021, View Source [SID1234596067]). Existing investors Boxer Capital, BVF Partners, L.P., Commodore Capital, Cormorant Asset Management, Janus Henderson Investors, Kite, a Gilead Company, Stork Capital, Wedbush Healthcare Partners and an undisclosed leading global investment firm, also participated. In connection with the financing, Frank Yu, Founder, CEO and CIO of Ally Bridge Group, joined the Shoreline Board of Directors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are proud of Shoreline’s tremendous progress over the past year, including next generation, more persistent and more effective iPSC-derived NK cells, enhancing our core technologies, advancing our preclinical programs, establishing transformative and validating partnerships with Kite and BeiGene, creating smart manufacturing methods, and attracting exceptional talent to support our next phase of development and growth," said Kleanthis G. Xanthopoulos, Ph.D., Shoreline’s co-founder, Chairman and Chief Executive Officer. "With this financing and our corporate partnerships, Shoreline has now more than $300 million to continue building our pipeline of safe, effective and affordable cellular immunotherapies for both solid tumors and hematologic malignancies."

"Having invested in – and followed closely for several years — the iPSC-derived NK cells-based therapeutics field which has made highly encouraging progress in the clinic, we are convinced of the true differentiation demonstrated by the Shoreline technology platform. Ally Bridge Group, a leading investor in best-in-class cell therapy companies from oncology to autoimmune diseases, expects Shoreline to be a new category leader," said Frank Yu, Founder, CEO and CIO of Ally Bridge Group.

The proceeds from the financing will allow Shoreline to continue the advancement of its proprietary iPSC platform focused on developing next generation natural killer (NK) cell and macrophage-cell therapies, create potent and persistent NK cell-specific Chimeric Antigen Receptors (CARs) as well as switchable CAR-NK cell engagers and macrophage-specific CARs to treat blood cancers, solid tumors, and other health conditions. With the close of this financing, Shoreline is well-capitalized with greater than $300 million, including committed partnership R&D funding, to execute on its goals and advance its pipeline.